Elraglusib clinical trials
Also written 9-ING-41.
How each study uses elraglusib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elraglusib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2022 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 6
Actuate Therapeutics Inc. (5) · Anwaar Saeed (2) · Brown University (2) · Robert Haddad, MD (1) · Colin D. Weekes, M.D., PhD (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test elraglusib.
- Dec 2026FOLFIRINOX + Elraglusib + Losartan In Pancreatic CancerPhase 2 · Colin D. Weekes, M.D., PhD
Studies
Open first, then newest update. How each study uses elraglusib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)RecruitingPhase 1Anwaar SaeedNCT06896188Written as 9-ING-41
- Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid TumorsNot yet recruitingPhase 1/2Actuate Therapeutics Inc.NCT07714395Written as Elraglusib Oral Tablets
- 9-ING-41 Plus Carboplatin in Salivary Gland CarcinomaActive, not recruitingPhase 2Robert Haddad, MDNCT05010629Written as 9-ING-41
- FOLFIRINOX + Elraglusib + Losartan In Pancreatic CancerActive, not recruitingPhase 2Colin D. Weekes, M.D., PhDNCT05077800Written as 9-ING-41
- 9-ING-41 in Patients With Advanced CancersActive, not recruitingPhase 2Actuate Therapeutics Inc.NCT03678883Written as 9-ING-41
- 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic AdenocarcinomaTerminatedPhase 2Anwaar SaeedNCT05239182Written as 9-ING-41
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.TerminatedPhase 1Actuate Therapeutics Inc.NCT04239092Written as 9-ING-41
- Actuate 1901: 9-ING-41 in MyelofibrosisCompletedPhase 2Actuate Therapeutics Inc.NCT04218071Written as 9-ING-41
- 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaWithdrawnPhase 2Actuate Therapeutics Inc.NCT04832438Written as 9-ING-41
- Phase 2 Study of 9-ING-41 With Chemotherapy in SarcomaWithdrawnPhase 2Brown UniversityNCT05116800Written as 9-ING-41
- A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced SarcomasWithdrawnPhase 2Brown UniversityNCT04906876Written as 9-ING-41
Codes
What other systems call elraglusib · ClinicalTrials.gg INT017377
- UNII (FDA) ND1SOF0DLUELRAGLUSIBOne source FDA
- NCI Thesaurus C156792ElraglusibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ND1SOF0DLU | ELRAGLUSIB | One source FDA |
| NCI Thesaurus | C156792 | Elraglusib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.